DK0856001T3 - Pyrimidinderivater som 5-HT2C-receptor-antagonister - Google Patents
Pyrimidinderivater som 5-HT2C-receptor-antagonisterInfo
- Publication number
- DK0856001T3 DK0856001T3 DK96932569T DK96932569T DK0856001T3 DK 0856001 T3 DK0856001 T3 DK 0856001T3 DK 96932569 T DK96932569 T DK 96932569T DK 96932569 T DK96932569 T DK 96932569T DK 0856001 T3 DK0856001 T3 DK 0856001T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor antagonists
- pyrimidine derivatives
- pyrimidine
- derivatives
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US473395P | 1995-10-02 | 1995-10-02 | |
| PCT/EP1996/004099 WO1997012880A1 (en) | 1995-10-02 | 1996-09-19 | Pyrimidine derivatives as 5ht2c-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0856001T3 true DK0856001T3 (da) | 2002-12-30 |
Family
ID=21712250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96932569T DK0856001T3 (da) | 1995-10-02 | 1996-09-19 | Pyrimidinderivater som 5-HT2C-receptor-antagonister |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5753663A (ru) |
| EP (1) | EP0856001B1 (ru) |
| JP (1) | JP3071830B2 (ru) |
| KR (1) | KR100258052B1 (ru) |
| CN (1) | CN1118460C (ru) |
| AR (1) | AR004516A1 (ru) |
| AT (1) | ATE222892T1 (ru) |
| AU (1) | AU700637B2 (ru) |
| BR (1) | BR9610823A (ru) |
| CA (1) | CA2233003A1 (ru) |
| CZ (1) | CZ98998A3 (ru) |
| DE (1) | DE69623306T2 (ru) |
| DK (1) | DK0856001T3 (ru) |
| EA (1) | EA001311B1 (ru) |
| ES (1) | ES2180798T3 (ru) |
| HU (1) | HUP9802323A3 (ru) |
| IL (1) | IL123581A (ru) |
| MX (1) | MX9802383A (ru) |
| NO (1) | NO310072B1 (ru) |
| NZ (1) | NZ319158A (ru) |
| PL (1) | PL326083A1 (ru) |
| PT (1) | PT856001E (ru) |
| WO (1) | WO1997012880A1 (ru) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
| US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
| GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| ES2153031T4 (es) * | 1995-04-20 | 2001-05-16 | Pfizer | Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf. |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9713087D0 (en) * | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| US20030176454A1 (en) * | 2000-05-15 | 2003-09-18 | Akira Yamada | N-coating heterocyclic compounds |
| MXPA03010810A (es) * | 2001-05-29 | 2004-03-22 | Schering Ag | Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos. |
| DK1625121T3 (da) | 2002-12-20 | 2010-05-10 | Pfizer Prod Inc | Pyrimidinderivater til behandling af abnorm cellevækst |
| US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| CA2566477A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| BRPI0510980A (pt) | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento do crescimento anormal de células |
| CA2564199A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| MX2007011156A (es) * | 2005-03-15 | 2007-10-23 | Hoffmann La Roche | Uso de 2-anilino-3,4-dihidro-quinazolinas como antagonistas del receptor 5ht5a. |
| WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
| MY162502A (en) | 2008-11-20 | 2017-06-15 | Merck Sharp & Dohme | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| ES2554623T3 (es) * | 2008-12-30 | 2015-12-22 | Arqule, Inc. | Compuestos de 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida |
| EP2512245B1 (en) * | 2009-12-14 | 2014-07-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| EP2515656B1 (en) * | 2009-12-21 | 2014-08-06 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
| TWI402264B (zh) * | 2010-05-12 | 2013-07-21 | Merck Sharp & Dohme | 芳基甲基苯并喹唑啉酮ｍ１受體之正向異位性調節劑 |
| US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
| CN110151745A (zh) | 2011-12-13 | 2019-08-23 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
| CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3177216A (en) * | 1961-12-28 | 1965-04-06 | Searle & Co | 4-trifluoromethyl-2-thio-5h-alka[d]-pyrimidines and congeners |
| US3257400A (en) * | 1964-06-10 | 1966-06-21 | Searle & Co | 2-amino-5, 6-dihydrobenzo[h]quinazolin-4(3h)-one and congeners |
| US3925384A (en) * | 1974-10-21 | 1975-12-09 | Squibb & Sons Inc | 2-Amino-4,5-dihydro-4-arylindeno pyrimidines |
| CA2119875A1 (en) * | 1991-10-24 | 1993-04-29 | Sylvie Bourrain | Benzodiazepine derivatives, compositions containing them and their use in therapy |
-
1996
- 1996-09-19 IL IL12358196A patent/IL123581A/en not_active IP Right Cessation
- 1996-09-19 CA CA002233003A patent/CA2233003A1/en not_active Abandoned
- 1996-09-19 PT PT96932569T patent/PT856001E/pt unknown
- 1996-09-19 NZ NZ319158A patent/NZ319158A/en unknown
- 1996-09-19 ES ES96932569T patent/ES2180798T3/es not_active Expired - Lifetime
- 1996-09-19 CN CN96197385A patent/CN1118460C/zh not_active Expired - Fee Related
- 1996-09-19 AU AU71311/96A patent/AU700637B2/en not_active Ceased
- 1996-09-19 EP EP96932569A patent/EP0856001B1/en not_active Expired - Lifetime
- 1996-09-19 EA EA199800340A patent/EA001311B1/ru not_active IP Right Cessation
- 1996-09-19 WO PCT/EP1996/004099 patent/WO1997012880A1/en not_active Application Discontinuation
- 1996-09-19 DK DK96932569T patent/DK0856001T3/da active
- 1996-09-19 CZ CZ98989A patent/CZ98998A3/cs unknown
- 1996-09-19 HU HU9802323A patent/HUP9802323A3/hu unknown
- 1996-09-19 MX MX9802383A patent/MX9802383A/es not_active IP Right Cessation
- 1996-09-19 BR BR9610823A patent/BR9610823A/pt not_active IP Right Cessation
- 1996-09-19 JP JP9513926A patent/JP3071830B2/ja not_active Expired - Fee Related
- 1996-09-19 KR KR1019980702391A patent/KR100258052B1/ko not_active IP Right Cessation
- 1996-09-19 AT AT96932569T patent/ATE222892T1/de not_active IP Right Cessation
- 1996-09-19 PL PL96326083A patent/PL326083A1/xx unknown
- 1996-09-19 DE DE69623306T patent/DE69623306T2/de not_active Expired - Fee Related
- 1996-09-24 US US08/719,062 patent/US5753663A/en not_active Expired - Fee Related
- 1996-10-01 AR ARP960104557A patent/AR004516A1/es unknown
-
1998
- 1998-04-01 NO NO981477A patent/NO310072B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU7131196A (en) | 1997-04-28 |
| AR004516A1 (es) | 1998-12-16 |
| IL123581A0 (en) | 1998-10-30 |
| NO981477L (no) | 1998-06-02 |
| CA2233003A1 (en) | 1997-04-10 |
| CN1118460C (zh) | 2003-08-20 |
| NO310072B1 (no) | 2001-05-14 |
| BR9610823A (pt) | 1999-07-13 |
| PT856001E (pt) | 2003-01-31 |
| ATE222892T1 (de) | 2002-09-15 |
| DE69623306T2 (de) | 2003-04-17 |
| IL123581A (en) | 2001-09-13 |
| JPH10512288A (ja) | 1998-11-24 |
| AU700637B2 (en) | 1999-01-07 |
| HUP9802323A3 (en) | 1999-08-30 |
| EA001311B1 (ru) | 2001-02-26 |
| HUP9802323A2 (hu) | 1999-03-29 |
| NZ319158A (en) | 1999-10-28 |
| DE69623306D1 (de) | 2002-10-02 |
| CN1198743A (zh) | 1998-11-11 |
| US5753663A (en) | 1998-05-19 |
| ES2180798T3 (es) | 2003-02-16 |
| PL326083A1 (en) | 1998-08-17 |
| EP0856001A1 (en) | 1998-08-05 |
| KR19990063918A (ko) | 1999-07-26 |
| JP3071830B2 (ja) | 2000-07-31 |
| EA199800340A1 (ru) | 1998-10-29 |
| MX9802383A (es) | 1998-08-30 |
| CZ98998A3 (cs) | 1998-10-14 |
| EP0856001B1 (en) | 2002-08-28 |
| KR100258052B1 (ko) | 2000-08-01 |
| NO981477D0 (no) | 1998-04-01 |
| WO1997012880A1 (en) | 1997-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0856001T3 (da) | Pyrimidinderivater som 5-HT2C-receptor-antagonister | |
| FI973205A (fi) | Indolijohdannaisia 5-HT-reseptoriantagonisteina | |
| NO985225L (no) | Indolderivater nyttige som endotelinreseptorantagonister | |
| NO962412L (no) | Pyrimidindion-, pyrimidintrion-, triazindion-, tetrahydrokinazolindionderivater som 1-adrenergiske reseptorantagonister | |
| DK0630376T3 (da) | Kondenserede indolderivater som 5-HT4-receptorantagonister | |
| DK1224175T3 (da) | Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister | |
| ATE404562T1 (de) | Substituierte purinderivate als vitronectinrezeptor-antagonisten | |
| DK1068202T3 (da) | 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister | |
| NO974043L (no) | Indolderivater som EAA-antagonister | |
| DK1027342T3 (da) | Cyclopentenderivater som motilinreceptorantagonister | |
| NO994106L (no) | Oksazolidiner som 5-HT2A-antagonister | |
| NO985970L (no) | Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister | |
| FI951798A0 (fi) | Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina | |
| NO972612D0 (no) | Pyridazoner som endotelinreseptorantagonister | |
| NO985972D0 (no) | Indolinderivater anvendelige som 5-HT-2C reseptorantagonister | |
| DK0815105T3 (da) | Heterocyklisk substituerede piperazinonderivater som tachykininreceptor-antagonister | |
| NO963775D0 (no) | Indol-derivater som CCK-reseptorantagonister | |
| FI941117A0 (fi) | Bentsyyli-imidatsopyridiinijohdannaiset angiotensiini II reseptoriantagonisteina | |
| ZA9600758D (en) | Idole derivatives as 5-ht receptor antagonist. |